| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Genetic Pharmacology Unit, Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
Address correspondence and reprint requests to Dr. M. Maral Mouradian, NINDS, NIH, 10 Center Drive, MSC 1406, Bethesda, MD 20892-1406; e-mail: MouradianM{at}ninds.nih.gov
The identification of three genes and several additional loci associated with inherited forms of levodopa-responsive PD has confirmed that this is not a single disorder. Yet, analyses of the structure and function of these gene products point to the critical role of protein aggregation in dopaminergic neurons of the substantia nigra as the common mechanism leading to neurodegeneration in all known forms of this disease. The three specific genes identified to date—
-synuclein, Parkin, and ubiquitin C terminal hydrolase L1—are either closely involved in the proper functioning of the ubiquitin-proteasome pathway or are degraded by this protein-clearing machinery of cells. Knowledge gained from genetically transmitted PD also has clear implications for nonfamilial forms of the disease. Lewy bodies, even in sporadic PD, contain these three gene products, particularly abundant amounts of fibrillar -synuclein. Increased aggregation of -synuclein by oxidative stress, as well as oxidant-induced proteasomal dysfunction, link genetic and potential environmental factors in the onset and progression of the disease. The biochemical and molecular cascades elucidated from genetic studies in PD can provide novel targets for curative therapies.
This article has been cited by other articles:
|
|
 |
|
  K. Kawahara, M. Hashimoto, P. Bar-On, G. J. Ho, L. Crews, H. Mizuno, E. Rockenstein, S. Z. Imam, and E. Masliah {alpha}-Synuclein Aggregates Interfere with Parkin Solubility and Distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE J. Biol. Chem., March 14, 2008; 283(11): 6979 - 6987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liu, X. Wang, Y. Yu, X. Li, T. Wang, H. Jiang, Q. Ren, Y. Jiao, A. Sawa, T. Moran, et al. A Drosophila model for LRRK2-linked parkinsonism PNAS, February 19, 2008; 105(7): 2693 - 2698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Iaccarino, C. Crosio, C. Vitale, G. Sanna, M. T. Carri, and P. Barone Apoptotic mechanisms in mutant LRRK2-mediated cell death Hum. Mol. Genet., June 1, 2007; 16(11): 1319 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N.P. Kelada, H. Checkoway, S. L.R. Kardia, C. S. Carlson, P. Costa-Mallen, D. L. Eaton, J. Firestone, K. M. Powers, P. D. Swanson, G. M. Franklin, et al. 5' and 3' region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study Hum. Mol. Genet., October 15, 2006; 15(20): 3055 - 3062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Caccia, R. Maj, M. Calabresi, S. Maestroni, L. Faravelli, L. Curatolo, P. Salvati, and R. G. Fariello Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology, October 10, 2006; 67(7 Suppl 2): S18 - S23. [Abstract] [Full Text]
|
|
|
|
 |
|
 S.-L. Hsuan, H. M. Klintworth, and Z. Xia Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. J. Neurosci., April 26, 2006; 26(17): 4481 - 4491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Lee, D.-C. Kim, B.-H. Choi, H. Ha, and K.-T. Kim Regulation of p53 by Activated Protein Kinase C-{delta} during Nitric Oxide-induced Dopaminergic Cell Death J. Biol. Chem., January 27, 2006; 281(4): 2215 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. Smith, Z. Pei, H. Jiang, D. J. Moore, Y. Liang, A. B. West, V. L. Dawson, T. M. Dawson, and C. A. Ross Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration PNAS, December 20, 2005; 102(51): 18676 - 18681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Paleacu, E. Schechtman, and R. Inzelberg Association between family history of dementia and hallucinations in Parkinson disease Neurology, May 24, 2005; 64(10): 1712 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Escobar-Morreale, M. Luque-Ramirez, and J. L. San Millan The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome Endocr. Rev., April 1, 2005; 26(2): 251 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F FORNAI, P LENZI, M GESI, M FERRUCCI, G LAZZERI, L CAPOBIANCO, A DE BLASI, G BATTAGLIA, F NICOLETTI, S RUGGIERI, et al. Similarities between Methamphetamine Toxicity and Proteasome Inhibition Ann. N.Y. Acad. Sci., October 1, 2004; 1025(1): 162 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C G L Lee, K Tang, Y B Cheung, L P Wong, C Tan, H Shen, Y Zhao, R Pavanni, E J D Lee, M-C Wong, et al. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese J. Med. Genet., May 1, 2004; 41(5): e60 - e60. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Newhouse, S.-L. Hsuan, S. H. Chang, B. Cai, Y. Wang, and Z. Xia Rotenone-Induced Apoptosis Is Mediated By p38 And JNK MAP Kinases In Human Dopaminergic SH-SY5Y Cells Toxicol. Sci., May 1, 2004; 79(1): 137 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Khan, R. Katzenschlager, H. Watt, K. P. Bhatia, N. W. Wood, N. Quinn, and A. J. Lees Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease Neurology, April 13, 2004; 62(7): 1224 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. SIDHU, C. WERSINGER, and P. VERNIER Does {alpha}-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J, April 1, 2004; 18(6): 637 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lee, M. Tanaka, K. Park, S. S. Lee, Y. M. Kim, E. Junn, S.-H. Lee, and M. M. Mouradian Casein Kinase II-mediated Phosphorylation Regulates {alpha}-Synuclein/Synphilin-1 Interaction and Inclusion Body Formation J. Biol. Chem., February 20, 2004; 279(8): 6834 - 6839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Matsuda, H. Hayashi, S. Miyatake, T. Kuroiwa, and H. Kagamiyama Instability of the Apo Form of Aromatic L-Amino Acid Decarboxylase In Vivo and In Vitro: Implications for the Involvement of the Flexible Loop That Covers the Active Site J. Biochem., January 1, 2004; 135(1): 33 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Lee, S. J. Kim, I.-K. Kim, J. Ko, C.-S. Jeong, G.-H. Kim, C. Park, S.-O. Kang, P.-G. Suh, H.-S. Lee, et al. Crystal Structures of Human DJ-1 and Escherichia coli Hsp31, Which Share an Evolutionarily Conserved Domain J. Biol. Chem., November 7, 2003; 278(45): 44552 - 44559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pankratz, W. C. Nichols, S. K. Uniacke, C. Halter, J. Murrell, A. Rudolph, C. W. Shults, P. M. Conneally, T. Foroud, and the Parkinson Study Group Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families Hum. Mol. Genet., October 16, 2003; 12(20): 2599 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R S Nicholas, J Partridge, R P Donn, C Hawkins, and M D Boggild The role of the PTPRC (CD45) mutation in the development of multiple sclerosis in the North West region of the United Kingdom J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 944 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.M. Ravina, S.C. Fagan, R.G. Hart, C.A. Hovinga, D.D. Murphy, T.M. Dawson, and J.R. Marler Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment Neurology, April 22, 2003; 60(8): 1234 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Junn, R. D. Ronchetti, M. M. Quezado, S.-Y. Kim, and M. M. Mouradian Tissue transglutaminase-induced aggregation of alpha -synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies PNAS, February 18, 2003; 100(4): 2047 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guttman, S. J. Kish, and Y. Furukawa Current concepts in the diagnosis and management of Parkinson's disease Can. Med. Assoc. J., February 4, 2003; 168(3): 293 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. He, X.-Y. Lu, A. F. Jolly, A. G. Eldridge, S. J. Watson, P. K. Jackson, G. S. Barsh, and T. M. Gunn Spongiform Degeneration in mahoganoid Mutant Mice Science, January 31, 2003; 299(5607): 710 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bonifati, P. Rizzu, M. J. van Baren, O. Schaap, G. J. Breedveld, E. Krieger, M. C. J. Dekker, F. Squitieri, P. Ibanez, M. Joosse, et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism Science, January 10, 2003; 299(5604): 256 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Ryu, H. P. Harding, J. M. Angelastro, O. V. Vitolo, D. Ron, and L. A. Greene Endoplasmic Reticulum Stress and the Unfolded Protein Response in Cellular Models of Parkinson's Disease J. Neurosci., December 15, 2002; 22(24): 10690 - 10698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Guttmacher and F. S. Collins Genomic Medicine -- A Primer N. Engl. J. Med., November 7, 2002; 347(19): 1512 - 1520. [Full Text] [PDF]
|
|
|
|
 |
|
 V. D. Longo and C. E. Finch Genetics of Aging and Diseases: From Rare Mutations and Model Systems to Disease Prevention Arch Neurol, November 1, 2002; 59(11): 1706 - 1708. [Full Text] [PDF]
|
|
|
|
|
|
K. Steece-Collier, E. Maries, and J. H. Kordower Etiology of Parkinson's disease: Genetics and environment revisited PNAS, October 29, 2002; 99(22): 13972 - 13974. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Sarang, T. Yoshida, R. Cadet, A. S. Valeras, R. V. Jensen, and S. R. Gullans Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays Physiol Genomics, October 29, 2002; 11(2): 45 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Burke and M. M. Mouradian Recent advances in the genetics and pathogenesis of Parkinson's disease Neurology, October 8, 2002; 59(7): 1118 - 1118. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
